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THE testing of compounds for carcinogenicity, by subcutaneous injection into
new-born mice, has been reported by several workers. Pietra, Spencer and
Shubik (1959) and Pietra, Rappaport and Shubik (1961) induced lung adenomata
and lymphomata in Swiss mice by the injection of 30 jtg. of 9,10-dimethyl-1,2-
benzanthracene (DMBA) into new-born mice and Stich (1960) obtained similar
results, using 60 atg. of DMBA. Comparable results were obtained by Roe,
Rowson and Salaman (1961) using DMBA on CBA and " 101 " strains of mice
and by Kelly and O'Gara (1961) and O'Gara, Kelly and Mantel (1962) using
dibenz(a,h)anthracene and 3-methylcholanthrene.
The experiment reported here was designed to investigate the response to
carcinogen in high and low cancer strain mice and how this response depends on
the genetic make up of the host.
MATERIALS AND METHODS
The animals used were Strong A and C57B1 strains ofmice, bred in this depart-
ment by brother-sister mating. They were housed in " Makrolon " cages and fed
diet No. 41 B (Oxoid) and water ad libitum.
The DMBA-treated and solvent-control animals, were each divided into six
groups: new-born (less than twelve hours old), seven and fourteen days old, for
each strain of mice. Each group contained 50 mice, having approximately equal
numbers of males and females.
Test mice of all groups received a single subcutaneous injection, in the
interscapular region, of 30 ,ug. ofDMBA in 15,ll. of3 % aqueous gelatine. Solvent
controls received 15 ,ul. of 3 % aqueous gelatine and an additional group of 50
untreated controls was used for each strain of mice.
Young mice were left with their mother up to four weeks and separated into
groups of six after weaning, the sexes being kept separate. The animals were
under daily inspection and any which were moribund or showed tumour growth
were killed and autopsied. Tissue from the site of injection, lung, liver, spleen,
kidney and any other tissues which appeared abnormal were taken for histological
examination.
There was no difference in the incidence of abnormal lesions between males
and females apart from a few cysts of ovary and uterus, therefore both sexes were
combined for the final evaluation of the experiment.ANTONIA FLAKS
RESULTS
The mortality rate was considerable in mice which were treated when new-
born, less in the seven day old groups and relatively low in the fourteen day old
groups. This was mainly due to the intolerance of females towards the handling
of their young. Mortality was much higher in C57B1 than in Strong A mice, but
there was no difference between solvent control and test groups.
There was no significant difference in body weight between experimental and
control groups at any stage. All mice which died before weaning were replaced;
all those which died after weaning but before five months after treatment were not
considered in the final results, since no neoplastic lesions were found.
The results are summarized in Table I and Table II.
TABLE I.-Strong A Mice
DMBA treated
Mice Number of mice with
died or lung adenoma Number Number
Age of killed Intensitv of adenomata of mice of mice
mice at Number between r a with lung with tumour
injection of mice 20-52 up to 52 at 52 carcinoma at site Number of mice
(days) injected weeks weeks weeks per cent of injection with other tumours
0 50 42 6 35 18 1 pleomorphic 5 liver adenomata
5+ 1+++ 1 +15++ 19+++ 42-9 sarcoma 1 ovarian carcinoma
7 50 48 16 30 17 1 carcinoma 7 liver adenomata
11+ 5+ + 2+ 21+ + 7+ + + 35-4 6 fibro- I thymonma
sarcomata 1 lymphoma
14 50 42 4 33 5 2 fibro- 1 liver adenoma
3+ 1++ 24+ 9±++ 11.9 sarcomata
Solvent control:
0 days 50 mice 2 mammary carcinoma.
7 days 50 mice2 mice with lung adenomata (+).
14 days 50 mice 1 mouse with lung adenomata (+).
Controls-untreated:
50 mice-1 mouse with mammary carcinoma.
1 mouse with lung adenomata (+).
+ = up to 10 adenomata + + = multiple adenomata +++ -= confluent adenomata.
DISCUSSION
From the tables it can be seen that, using a dose of constant size, in the Strong
A mice the highest susceptibility to carcinogen as measured by the number of
adenomata present and by the tendency for malignant change to occur is shown
by new-born mice. This result is comparable to the findings of Roe, Mitchley
and Walters (1963) on this particular aspect. The incidence of sarcomata at the
site of injection was small in comparison to that reported by O'Gara et al. (1962).
Both strains ofmice showthehighest percentage offibrosarcomata in seven day old
animals.
It is evident that there is a large difference between the two strains of mice
in their susceptibility to the carcinogenic action of DMBA. Pulmonary tumours
are known to arise spontaneously in old Strong A mice and the lungs appear to be,
genetically, the organs which are most susceptible to the carcinogenic action of
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TABLE II.-C57B1 Mice
DMBA treated
Mice
died oi Number
Age of killed Nuimiber of mice with of mice
mice at Number between lung adenoina with tumour Number of
injection of mice 20-52 Intensityr of ademomata at site mice with Lymphatic
(days) injected weeks at 52 weeks of injection other tumours hyperplasia
() 50 39 1 0 7 liver adeno- 16
mata
3 leukaemia
7 50 41 2 3 fibro- 3 liver adeno- 13
+ sarcoma mata
1 malignant
hepatoma
4 leukaemia
1 lympho-
sarcorna
1 stomach
carcinoma
14 50 41 1 iuiyo- 1 epithelial 5
sarcoma tuInour of
ureter
Solvent control:
0 days 50 mice no tuimiours or lymphatic hyperplasia.
7 days 50 mice 2 mice with lymphatic hyperplasia.
14 days 50 mice no tumours or lymphatic hyperplasia.
Controls-treated:
50 mice 1 mouse with lylphatic hyperplasia.
DMBA. Similarly, C57B1 mice are liable to lesions of the lymphatic system and
the introduction of carcinogen has aggravated this and accelerated their appear-
ance.
The incidence of adenomata could not be assessed by counting since many
lungs exhibited a mass ofadenomata merging into one another, but it is ofinterest
that malignant tumours did not always develop in these lungs showing confluent
adenomata.
It would seem that, in using new-born mice as test animals for the testing of
suspected carcinogens, it is advisable to use a strain of mice which is genetically
pure and is known to produce specific spontaneous tumours.
SUMMARY
Groups of Strong A and C57B1 mice were injected, when new-born, seven or
fourteen days old, with a single injection of 30 aug. of DMBA in 15 ,ul. of 3 %
aqueous gelatine solution. Solvent controls were injected with 15 ,ul. of 3 %
aqueous gelatine only. Untreated controls were also examined.
Surviving animals were killed at 52 weeks after injection. All animals dead
or killed between 20 and 52 weeks after the injection were examined macroscopic-
ally and microscopically.
In Strong A, new-born mice showed the highest susceptibility to DMBA
carcinogenesis in lungs. Both strains of mice show the highest number of fibro-
sarcomata in seven day old mice. C57B1 strain of mice responded to much lesser550 ANTONIA FLAKS
degree than Strong A mice. The specific type of tumour which developed
depended on the genetic type of the strain of mouse used. Carcinogenic com-
pounds aggravate and accelerate the strain's natural tendency to specific neoplastic
lesions.
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